CytRx to Participate in Alzheimer's and Parkinson's Disease Panel at BIO CEO Conference
Posted on: Thursday, 17 February 2005, 09:00 CST
LOS ANGELES, Feb. 17 /PRNewswire-FirstCall/ -- Jack Barber Ph.D., Senior Vice President, Drug Development of CytRx Corporation , will participate in an Alzheimer's and Parkinson's disease panel at the BIO CEO & Investor Conference being held February 23-24, 2005 in New York, NY at the Waldorf=Astoria Hotel. The panel discussion will be held at 9:30am EST on Wednesday, February 23 in the Basildon Room.
According to BIO CEO, the panel, entitled "Biotech's Solutions to Alzheimer's and Parkinson's Disease," will provide "a clinical perspective on the problem and opportunities that are being explored towards finding a cure for Alzheimer's and Parkinson's." Dr. Barber will discuss CytRx's small molecule drug, arimoclomol, which may provide cellular protection from abnormal proteins by activating molecular "chaperone" proteins that can repair or degrade damaged proteins that are believed to cause many diseases, including ALS. The panel discussion will be webcast and can be found at http://www.corporate-/ ir.net/ireye/confLobby.zhtml?ticker=28873&item_id=1009743.
Now in its seventh year, the BIO CEO & Investor Conference has emerged as the industry's own investor conference. Hosted by the Biotechnology Industry Organization (BIO), the meeting brings together key industry players in a neutral and collaborative forum to examine investment opportunities and issues affecting the biotechnology industry. Participants include senior biotechnology executives, institutional and venture capital investors, industry analysts, corporate finance executives and experts from the scientific and medical communities.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company, based in Los Angeles with a subsidiary in Worcester, Massachusetts. The company is engaged in the development of products, primarily in the area of small molecules and ribonucleic acid interference (RNAi), in a variety of therapeutic categories. In October 2004, the company acquired 3 clinical stage compounds and a library of 500 small molecule drug candidates from Biorex Research & Development Company. The company has a broad-based strategic alliance with the University of Massachusetts Medical School to develop novel compounds in the areas of ALS, obesity, type 2 diabetes and CMV using RNAi technology. CytRx also licensed from UMMS the rights to a DNA-based HIV vaccine technology currently in a Phase I clinical trial. The company also has a research program with Massachusetts General Hospital, Harvard University's teaching hospital, to use RNAi technology to develop a drug for the treatment of ALS. For more information, visit CytRx's website at http://www.cytrx.com/.
This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the early stage of CytRx's diabetes, obesity, CMV and ALS research, the need for future clinical testing of any RNAi-based products and small molecules that may be developed by CytRx, uncertainties regarding the scope of the clinical testing that may be required by regulatory authorities for the products acquired from Biorex and other products and the outcomes of those tests, the significant time and expense that will be incurred in developing any of the potential commercial applications for CytRx's RNAi technology or small molecules, CytRx's need for additional capital to fund its ongoing working capital needs, including ongoing research and development expenses related to the drugs purchased from Biorex, risks relating to the enforceability of any patents covering CytRx's products and to the possible infringement of third party patents by those products, and the impact of third party reimbursement policies on the use of and pricing for CytRx's products. Additional uncertainties and risks are described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CytRx Corporation
CONTACT: Ed Umali, Director of Communications of CytRx Corporation,+1-310-826-5648, ext. 309, eumali@cytrx.com
Web site: http://www.cytrx.com/
Company News On-Call: http://www.prnewswire.com/comp/638413.html
Source: PRNewswire-FirstCall
Related Articles
- Harris Corporation Receives UCF Industry Research Sponsor Award
- NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
- Kane Biotech Receives $405,000 Contribution From the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) to Develop DispersinB(TM) Antibiofilm Wound Gel Product
- Sugar Foods Corporation Hires Jorge Moheno, Manager Quality Assurance and Product Development, Mazatlan, Mexico
- FACT Corporation Launching Key 2007 New-Product Development Initiatives
- Revolutions Medical Corporation Has Chosen Strategic Product Development, Inc. For Their FDA Application Process
- State Gives Cleveland Clinic and Fairfax Renaissance Development Corporation $60 Million To Develop Global Cardiovascular Innovation Center
- Petroleum Development Corporation Updates Fourth Quarter and Year End 2005 Operations, Production and Reserves
- Health Discovery Corporation Expands Licensing and Product Development Relationship With Clarient, Inc.
- Understanding New Product Co-Development Relationships In Technology- Based, Industrial Markets
 |
 |
User Comments (0)
RSS Feeds